Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...

Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.

Recent health news highlights include a UK hospital-related death due to a cyberattack, Walgreens beating profit estimates ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Grey market grows for cheap weight-loss drugs imported from China Some users try small doses of substances not yet approved ...